More than so-so progress for Sotio in cancer immunotherapy
The small biotech Sotio AS, of Prague, has shunned the limelight since its founding in 2010. Instead of promoting its potential to treat various forms of cancer, the company is letting its technology do the talking.
Sotio's active cellular immunotherapy-multiple antigen presentation (ACI-MAP) platform is the basis for an oncology product pipeline that uses a patient's activated dendritic cells to induce an immune response that targets particular cancer cells.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST